Prab: CSV import

2025-03-06T05:10:20Z

CSV import

← Older revision		Revision as of 05:10, 6 March 2025
Line 3:		Line 3:
	[[File:Olezarsen_sodium.svg\|Chemical structure of Olezarsen sodium\|thumb\|right]]		[[File:Olezarsen_sodium.svg\|Chemical structure of Olezarsen sodium\|thumb\|right]]

	'''Olezarsen''' is an investigational antisense oligonucleotide designed for the treatment of hypertriglyceridemia, a condition characterized by elevated levels of triglycerides in the blood. It is being developed by [[Ionis Pharmaceuticals]] ~~and is currently undergoing clinical trials to assess~~ its ~~efficacy and safety~~.		'''Olezarsen''' is an investigational antisense oligonucleotide designed for the treatment of hypertriglyceridemia, a condition characterized by elevated levels of triglycerides in the blood. It is being developed by [[Ionis Pharmaceuticals]], a company known for its work in RNA-targeted therapeutics.

	== Mechanism of Action ==		== Mechanism of Action ==
Line 11:		Line 11:
	== Clinical Development ==		== Clinical Development ==

	Olezarsen is currently in ~~the clinical trial phase~~, with ~~studies focusing on its ability to reduce~~ triglyceride levels in ~~patients with severe hypertriglyceridemia~~. The ~~trials aim to evaluate the~~ drug~~'s safety, tolerability~~, and ~~effectiveness in lowering triglycerides and potentially reducing the risk of pancreatitis and cardiovascular disease associated with high triglyceride levels~~.		Olezarsen is currently undergoing clinical trials to evaluate its efficacy and safety in patients with hypertriglyceridemia. Early studies have shown promising results, with significant reductions in triglyceride levels observed in treated individuals. The drug is administered via subcutaneous injection, and its dosing regimen is being optimized based on ongoing research.

	== Potential ~~Benefits~~ ==		== Potential Indications ==

	The ~~reduction of triglyceride levels through~~ the ~~use~~ of ~~Olezarsen could offer significant health benefits for~~ patients ~~with hypertriglyceridemia. Lowering triglycerides can reduce the~~ risk of developing pancreatitis~~, a painful and potentially life-threatening inflammation of the pancreas~~. Additionally, ~~managing triglyceride levels is important~~ for ~~cardiovascular health~~, ~~as high triglycerides are~~ a ~~risk factor for atherosclerosis and heart disease~~.		The primary indication for Olezarsen is the treatment of severe hypertriglyceridemia, particularly in patients who are at risk of developing pancreatitis due to extremely high triglyceride levels. Additionally, it may be beneficial for patients with familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by impaired triglyceride metabolism.

	== ~~Administration~~ ==		== Safety and Tolerability ==

	Olezarsen ~~is administered via subcutaneous injection~~. The ~~dosing regimen is determined based on the specific needs of the patient~~ and ~~the severity of their condition~~. As with any ~~medication~~, ~~adherence~~ to the ~~prescribed dosing schedule is crucial for achieving optimal results~~.		In clinical trials, Olezarsen has been generally well-tolerated. The most common side effects reported include injection site reactions, such as redness and swelling. As with any investigational drug, ongoing studies are crucial to fully understand the long-term safety profile of Olezarsen.

	== ~~Side Effects~~ ==		== Future Directions ==

	~~As an investigational drug,~~ the full ~~side effect profile~~ of Olezarsen ~~is still being studied~~. ~~However, common side effects observed in clinical trials include injection site reactions, such as redness and swelling, as well as flu~~-~~like symptoms~~. ~~Patients~~ are ~~monitored closely during trials~~ to ~~ensure any adverse effects are managed promptly~~.		Research is ongoing to explore the full potential of Olezarsen in various lipid disorders. Its ability to specifically target ApoC-III makes it a promising candidate for combination therapies aimed at comprehensive lipid management. Further studies are needed to assess its impact on cardiovascular outcomes and its role in the broader context of lipid-lowering strategies.

	== Related Pages ==		== Related Pages ==
Line 29:		Line 29:
	* [[Hypertriglyceridemia]]		* [[Hypertriglyceridemia]]
	* [[Apolipoprotein C-III]]		* [[Apolipoprotein C-III]]
	* [[Lipoprotein lipase]]
	* [[Ionis Pharmaceuticals]]		* [[Ionis Pharmaceuticals]]
			* [[Antisense oligonucleotide]]

	[[Category:Antisense oligonucleotides]]		[[Category:Antisense oligonucleotides]]
	[[Category:Investigational drugs]]		[[Category:Investigational drugs]]
	[[Category:~~Cardiovascular drugs~~]]		[[Category:Lipid-lowering agents]]

Prab: CSV import

2025-03-05T06:43:02Z

CSV import

New page

== Olezarsen ==

[[File:Olezarsen_sodium.svg|Chemical structure of Olezarsen sodium|thumb|right]]

'''Olezarsen''' is an investigational antisense oligonucleotide designed for the treatment of hypertriglyceridemia, a condition characterized by elevated levels of triglycerides in the blood. It is being developed by [[Ionis Pharmaceuticals]] and is currently undergoing clinical trials to assess its efficacy and safety.

== Mechanism of Action ==

Olezarsen works by targeting and reducing the production of apolipoprotein C-III (ApoC-III), a protein that plays a key role in the regulation of triglyceride metabolism. ApoC-III inhibits the breakdown of triglycerides by lipoprotein lipase and also impairs the clearance of triglyceride-rich lipoproteins from the bloodstream. By decreasing ApoC-III levels, Olezarsen helps to lower triglyceride levels and improve lipid profiles in patients.

== Clinical Development ==

Olezarsen is currently in the clinical trial phase, with studies focusing on its ability to reduce triglyceride levels in patients with severe hypertriglyceridemia. The trials aim to evaluate the drug's safety, tolerability, and effectiveness in lowering triglycerides and potentially reducing the risk of pancreatitis and cardiovascular disease associated with high triglyceride levels.

== Potential Benefits ==

The reduction of triglyceride levels through the use of Olezarsen could offer significant health benefits for patients with hypertriglyceridemia. Lowering triglycerides can reduce the risk of developing pancreatitis, a painful and potentially life-threatening inflammation of the pancreas. Additionally, managing triglyceride levels is important for cardiovascular health, as high triglycerides are a risk factor for atherosclerosis and heart disease.

== Administration ==

Olezarsen is administered via subcutaneous injection. The dosing regimen is determined based on the specific needs of the patient and the severity of their condition. As with any medication, adherence to the prescribed dosing schedule is crucial for achieving optimal results.

== Side Effects ==

As an investigational drug, the full side effect profile of Olezarsen is still being studied. However, common side effects observed in clinical trials include injection site reactions, such as redness and swelling, as well as flu-like symptoms. Patients are monitored closely during trials to ensure any adverse effects are managed promptly.

== Related Pages ==

* [[Hypertriglyceridemia]]
* [[Apolipoprotein C-III]]
* [[Lipoprotein lipase]]
* [[Ionis Pharmaceuticals]]

[[Category:Antisense oligonucleotides]]
[[Category:Investigational drugs]]
[[Category:Cardiovascular drugs]]

Olezarsen - Revision history

Prab: CSV import

Prab: CSV import